


UNLV

Division of
**RESEARCH &
ECONOMIC
DEVELOPMENT**



**Nevada
Institute of
Personalized
Medicine**

unlv.edu/nipm



For more information,
please contact:

Martin Schiller, Ph.D.
Executive Director
of the Nevada Institute of
Personalized Medicine

702-895-5546
Martin.Schiller@unlv.edu

NIPM Q1 2017 Newsletter



Scene From the 2017 Annual NIPM Retreat

A local businessman is giddy over a NIPM poster on dietary genomics research, which is being pursued as a startup.

NIPM Clinic: Almost 200 Patients and Growing!

NIPM's own Dr. Michael Nasiak—the only clinical geneticist serving Las Vegas—now serves roughly 200 Nevada families with patient genetic services. Ninety percent of these patients are children who are undergoing life-changing changes in treatment. The facility is expanding shortly to include adult genetics, in concert with adjunct professor Robb Rowley, M.D., and his cancer genetics-focused practice. The doctors' efforts, coupled with NIPM analytic and sequencing services, has attracted three leading national genomics groups to advanced talks about engaging NIPM's Las Vegas initiatives. The launch and maintenance of this clinic is critically dependent on generous support from the Nevada Governor's Office of Economic Development.

NIPM Startup Company: Getting Operational

Heligenics is a new startup company that licensed NIPM intellectual property from UNLV for drug and diagnostic development. A sister company, FoodGenesAndMe, is partnering with UNLV's Lee Business School and intends to generate significant revenue in 2017 as a web-based service that provides tailored diet suggestions based on personal genetics.

NIPM Genome Sequencing: Open for Business

The only dedicated genome sequencing laboratory in Las Vegas is now staffed, operational, and aggressively seeking business from UNLV, nonprofit, and business customers. Please contact Martin Schiller at 702-895-5546 or Martin.Schiller@unlv.edu for more information.

NIPM's Annual Retreat: Community Interest

The annual retreat NIPM held in February—focused on clinical progress and data interpretations—garnered significant interest, most notably from multiple angel investors interested in NIPM startups (such as the one pictured above). NIPM advisors were unanimous in their support for NIPM's scientific and business strategies.

New Discovery Predicts Mental Illness Risk

New patent filings are anticipated from Dr. Sam Chen, who claims a genetic panel can provide an early warning of psychiatric risks.